Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott posted strong organic growth of 11% in Q4 when excluding Covid testing sales. This year the stock will hit a milestone: 400 consecutive quarterly dividend payments.

Is Abbott Laboratories Stock a Buy Now?

A judge has rejected Abbott Laboratories' effort to dismiss a New York City grandmother's lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition drinks were "clinically proven" to help children grow taller.

Abbott Labs must face lawsuit over PediaSure height claims

Novo Nordisk and Eli Lilly have generated billions of dollars in revenue selling weight loss drugs. Abbott Labs is launching a complementary product for those on the weight loss path.

Could Abbott Labs Be the Next Big Winner in the Billion-Dollar Weight Loss Market?

Mixed reality experience allows blood donors to visit a digital world while remaining fully aware of their surroundings for a safe, relaxing donation 68.4% of pilot study participants who reported pre-donation anxiety said the mixed reality experience helped ease feelings of anxiety 89.2% of donors who tried mixed reality said they were likely to donate blood again Innovation is designed to attract new donors and motivate a younger generation to give blood ABBOTT PARK, Ill., Feb. 1, 2024 /PRNewswire/ -- A new study published online and available in the February print edition of the journal Transfusion shows the mixed reality technology for use during blood donation created by Abbott (NYSE: ABT) and Blood Centers of America (BCA) helps ease donors' feelings of anxiety and boosts the likelihood they will return to give blood again.

New Study Shows Mixed Reality Technology for Blood Donation from Abbott and Blood Centers of America Helps Ease Stress, Encourages People to Donate Again

Pharmaceutical firm Abbott India reported a 26% rise in third-quarter profit on Thursday, as higher sales outpaced the impact of a pricing cap on certain medicines.

Drugmaker Abbott India's Q3 profit rises on strong demand

Abbott Laboratories said on Wednesday it has launched a new protein shake that would help adults looking to lose weight and maintain their muscle mass.

Abbott launches protein shake brand to help people on weight-loss drug

The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of fast- and slow-digesting protein designed to feed muscles for up to seven hours As people eat less and lose weight, a portion of what's lost may be from muscle, which is vital to overall health and physical functioning More than 7 in 10 adults are overweight or have obesity in the U.S. and many turn to diets, whether combined with medication, surgery or calorie restriction, to lose weight and improve overall health1 ABBOTT PARK, Ill., Jan. 31, 2024 /PRNewswire/ -- Abbott (NYSE: ABT), a global leader in science-based nutrition, announced today the launch of its new PROTALITY™ brand.

Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey

Intuitive Surgical

Johnson & Johnson

Stryker

Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to dissipate, and the growth outlook was uncertain, leaving the market for their stock without a solid catalyst to drive it despite many trading at value levels and paying healthy dividends.

4 med tech stocks with improving prognosis for 2024

A near 2.0% post-earnings decline in Abbott Laboratories (NYSE: ABT) warrants an investment in the health care giant, says Jim Cramer. Cramer's bullish view on Abbott stock His Charitable Trust bought 275 shares of the medical devices company at $112 each on Monday.

Jim Cramer just bought Abbott stock: should you too?

Medtronic

Given its better prospects, we believe Medtronic stock (NYSE: MDT) is a better pick than its peer, Abbott stock (NYSE: ABT). Abbott trades at a higher valuation multiple of 4.9x revenues vs.

Up Just 6% In 2023 Is Medtronic Stock A Better Pick Over Abbott?

Apple

Best Buy

Cigna

Microsoft

ReWalk Robotics

Teladoc

While it doesn't seem like it when you're young, aging happens to everyone and therefore, so-called AgeTech stocks should benefit from inevitability. A buzzword for age-related technology, this concept refers to a rapidly growing field focused on developing and applying innovative solutions to improve the lives of senior citizens.

7 ‘AgeTech' Stocks to Profit From the Booming Longevity Market

Here is how Abbott (ABT) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.

Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?

Abbott Laboratories' stock price has risen by 16.6% since October 2023, outperforming the index. The company achieved strong growth in FY23, excluding contributions from COVID testing businesses. Abbott Laboratories is providing guidance for 8-10% organic revenue growth in FY24, with a focus on overcoming challenges related to the pandemic.

Abbott: Strong R&D Pipeline Continues To Drive Growth; Reiterate 'Strong Buy'

A key component of income investing is a portfolio that includes safe dividends, those that are unlikely to shrink or disappear.

Just How Safe Is Abbott Labs Stock's Dividend?

Abbott Laboratories NYSE: ABT share price fell following its Q4 2023 results, but investors should be cheering the news. The decline is a response to a report that was largely as expected, with the expectation being healthcare industry normalization and return to growth.

Abbott Laboratories on track for new highs in 2024

Liberta RC™ deep brain stimulation (DBS) system, recently approved by the U.S. FDA, features NeuroSphere™ Virtual Clinic, which allows for remote programming of the system System offers the longest time between charges of any DBS technology on the market, allowing people with movement disorders to recharge the device only 10 times a year2* ABBOTT PARK, Ill., Jan. 25, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC™ DBS system, the world's smallest rechargeable deep brain stimulation (DBS) device with remote programming, to treat people living with movement disorders.1 + The Liberta RC DBS system also requires the fewest recharges of any FDA-approved DBS system, needing only 10 recharge sessions a year for most people.2* Communication between people and their doctors is critical to ensuring exceptional care, especially for those who suffer from chronic conditions, such as Parkinson's disease and essential tremor, that can be treated with deep brain stimulation therapy.

Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+

Less than two years after a headline-grabbing shutdown of a baby formula plant in Michigan that fueled a national crisis, Abbott Laboratories has “reclaimed its previous market-leading position.”

Once Slowed By Shutdown, Abbott Labs Says Baby Formula Franchise Back Leading U.S. Market

Abbott Laboratories (ABT) Q4 2023 Earnings Call Transcript

Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.

Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Abbott (ABT) Q4 Earnings

Abbott (ABT) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.03 per share a year ago.

Abbott (ABT) Q4 Earnings Match Estimates

Abbott topped quarterly sales forecasts and earnings came in line. But earnings guidance was light at the midpoint and ABT stock fell.

Abbott Labs Skids On Light Earnings Guidance Despite Quarterly Sales Beat

Healthcare multinational Abbott Laboratories (NYSE:ABT) battled negative Covid-19-related comparables in the 2023 financial year, causing an 8.1% fall in group-wide revenues to $40.1 billion. However, organic revenues when excluding the impact of these comparables revealed steady double-digit top-line growth of 11.6%.

Abbott Labs battles negative Covid-19 comparables but hits earnings targets

Abbott Laboratories (NYSE: ABT) is trading down in premarket on Wednesday even though it reported solid results for its fiscal fourth quarter. Why is Abbott stock down on Wednesday?

Abbott reports solid results for its fiscal Q4

Abbott, a maker of healthcare products, posted fourth-quarter earnings in line with expectations, and beat sales estimates.

News for Abbott Labs Stock (ABT)